849675-66-7

Usage

Uses

Used in Pharmaceutical Industry:
HM 30181A is used as a therapeutic agent for the treatment of multiple sclerosis and ulcerative colitis. Its application is based on its capacity to lower lymphocyte levels in the blood, thereby reducing inflammation and alleviating symptoms associated with these conditions.
Used in Autoimmune Disease Treatment:
HM 30181A is used as a potential treatment option for other autoimmune diseases. Its application is grounded in its immunomodulatory effects, which can help manage the immune system's response and potentially alleviate disease symptoms.
Used in Medical Research:
HM 30181A is used as a research tool for studying the role of S1P receptors in immune system regulation and the potential for developing new treatments for various autoimmune and inflammatory conditions. Its application in research is driven by the need to understand the underlying mechanisms of autoimmune diseases and to identify novel therapeutic targets.

Upstream product

• 488-93-7 3-Furoic acid 
• 849675-46-3 2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyaniline 
• 4940-39-0 acide chromone carboxylique-2 
• 5112-47-0 4-oxo-4H-chromene-2-carbonyl chloride 
• 2328-12-3 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline monohydrochloride 
• 1314518-45-0 S-(benzo[d]thiazol-2-yl) 4-oxo-4H-chromene-2-carbothioate 
• 20357-25-9 6-nitroveratraldehyde 
• 5339-26-4 (4-nitrophenyl)ethyl bromide 
• 82925-02-8 4-<2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolyl)ethyl>benzenamine 
• 82925-01-7 1,2,3,4-Tetrahydro-6,7-dimethoxy-2-[2-(4-nitrophenyl)ethyl]-isoquinoline 

Relevant academic research and scientific papers

Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor

Many chemotherapeutics, such as paclitaxel, are administered intravenously as they suffer from poor oral bioavailability, partly because of efflux mechanism of P-glycoprotein in the intestinal epithelium. To date, no drug has been approved by the U.S. Foo

ALTERNATE PROCESS FOR THE PREPARATION OF ENCEQUIDAR

The aspect of the present application relate to process for the preparation of Encequidar (HM-30181A) and salts thereof. Specific aspects relate to an improved process for the Encequidar and its mesylate salt, comprising the amidation of aniline precursor of Encequidar of formula II using 4-oxo-4H-chromene-2-carboxylic acid in the presence of an activating agent.

SOLID STATE FORMS OF N-[2-(2-{4-[2-(6,7-DIMETHOXY-3,4-DIHYDRO-2(LH)- ISOQUINOLINYL)ETHYL] PHENYL }-2H-TETRAZOL-5-YL)-4,5-DIMETHOXYPHENYL] -4- OXO-4H-CHROMENE-2-CARBOXAMIDE AND OF ITS MESYLATE SALT

The present disclosure relates to solid state forms of Encequidar (previously referred to as HM-30181A) base, Encequidar ((HM-30181A) mesylate, co-crystals of Encequidar (HM-30181A) mesylate, processes for preparation thereof, as well as pharmaceutical compositions including the same.

SOLID FORMS OF ENCEQUIDAR MESYLATE AND PROCESSES THEREOF

Aspects of the present application relate to solid forms of Encequidar, its mesylate salt and pharmaceutical compositions thereof. Specific aspects relate to the crystalline Form E1 of Encequidar, crystalline Form EM1, crystalline Form EM2 and crystalline Form EM3 of Encequidar mesylate. Further aspects relate to processes for the preparation of solid forms of Encequidar and its mesylate salt.

METHOD FOR PREPARING TETRAZOLE METHANESULFONIC ACID SALTS, AND NOVEL COMPOUND USED IN SAME

According to the present invention, a method for preparing tetrazole methanesulfonic acid salts comprises an acylation reaction using a novel 4-iodine-4H-chromene-2-carbothionic acid S-benzothiazole-2-yl ester. The method of the present invention can shor

METHOD FOR PREPARING TETRAZOLE METHANESULFONIC ACID SALTS, AND NOVEL COMPOUND USED IN SAME

According to the present invention, a method for preparing tetrazole methanesulfonic acid salts comprises an acylation reaction using a novel 4-iodine-4H-chromene-2-carbothionic acid S-benzothiazole-2-yl ester. The method of the present invention can shor